Bryan Roberts

Bryan has served on Inscripta^®’s board of directors since 2017. He joined Venrock as a Kauffman Fellow in 1997 and is based in Venrock’s Palo Alto office focusing on partnering with early-stage entrepreneurs innovating across the healthcare and life sciences industries. Bryan is currently involved with several companies across therapeutics, genomics, and health tech, including Aledade, Devoted Health, Element Biosciences, Encoded Therapeutics, Included Health, Inscripta^®, Interdict, Kelonia Therapeutics, MoonlightBio, Mythic Therapeutics, Lyra Health, SmithRx and Suki.ai. Past investments include 10x Genomics (NASDAQ: TXG), Ariosa Diagnostics (acquired by Roche), athenahealth (NASDAQ: ATHN), Fate Therapeutics (NASDAQ: FATE), Ikaria (acquired by Mallinckrodt), Illumina (NASDAQ: ILMN), Ironwood Pharmaceuticals (NASDAQ: IRWD), Receptos (acquired by Celgene), Sirna Therapeutics (acquired by Merck), and Zeltiq (acquired by Allergan).

Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University. He received his B.A. from Dartmouth College.